ArticlePloS one2025
Resveratrol decreases extracellular traps (ETs) in acute promyelocytic leukemia (NB4) cells.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- CAR-engineered neutrophils derived from induced pluripotent stem cells: a new frontier in cellular immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Natural Products Targeting PAD4 in NETosis: Structural and Mechanistic Insights into Direct and Indirect Inhibition.Biomolecules · 2026Review
- Metabolic reprogramming in tumor-associated cells of hematologic malignancies: mechanisms, crosstalk networks, and therapeutic implications in the tumor microenvironment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundActivated neutrophils can create structures known as neutrophil extracellular traps (NETs/ETs) consisting of nuclear components and granules. The ETOsis phenomenon leads to activating the platelets and coagulation factors. Accordingly, coagulation and fibrinolysis can be promoted. Resveratrol (RSV) is a botanical antioxidant with anti-inflammatory and anti-leukemia effects. The present study was conducted to assess the effect of RSV on the occurrence of ETOsis in the NB4 cell line.
methodsHuman acute promyelocytic leukemia cell line (NB4) were stimulated and treated by lipopolysaccharides (LPS) and RSV, respectively. Sytox green and a fluorescent microscope were used to assess the ETOsis in NB4 cells. Furthermore, the expression level of peptidylarginine deiminase 4 (PAD4) gene and the occurrence of ETOsis in NB4 cells were evaluated by real-time PCR and flow cytometry, respectively. Moreover, an enzyme-linked immunosorbent assay (ELISA) kit was utilized to measure tumor necrosis factor-α (TNF-α) cytokine.
resultsFollowing treatment with RSV, a significant decrease in PAD4 gene expression and TNF-α cytokine concentration in the supernatant of NB4 cell line culture medium was observed. Besides, the amount of ETOsis in the NB4 cells treated with LPS and RSV decreased.
conclusionThe findings demonstrated that RSV can inhibit the process of ETOsis in NB4 cells. By inhibiting the process of ETOsis, RSV may be able to reduce the bleeding and, consequently, the failure after treatment in acute promyelocytic leukemia (APL) patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.